eupalinilide E: promotes the expansion of myelo-erythroid hematopoietic progenitors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11188671 |
| CHEMBL ID | 463970 |
| MeSH ID | M0590817 |
| Synonym |
|---|
| CHEMBL463970 |
| eupalinilide e |
| [(3ar,4r,6r,6as,7r,9ar,9br)-6-(chloromethyl)-6,7-dihydroxy-9-methyl-3-methylidene-2-oxo-4,5,6a,7,9a,9b-hexahydro-3ah-azuleno[4,5-b]furan-4-yl] (e)-2-methylbut-2-enoate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eupalinilide E promotes the expansion of human HSPCs and inhibits subsequent differentiation, leading to increased numbers of clinically useful cells." | ( Synthesis of Eupalinilide E, a Promoter of Human Hematopoietic Stem and Progenitor Cell Expansion. Chin, MR; Han, T; Johnson, TC; Rana, T; Shen, JP; Siegel, D, 2016) | 1.52 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID333185 | Cytotoxicity against human A549 cells after 24 hrs | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Cytotoxic sesquiterpene lactones from Eupatorium lindleyanum. |
| AID333184 | Cytotoxicity against mouse P388 cells after 24 hrs | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Cytotoxic sesquiterpene lactones from Eupatorium lindleyanum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||